Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future.

The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vectors. Dr. Hibbs describes also the surprising link between extreme heat during pregnancy and an increased risk of children developing ALL (acute lymphoblastic leukemia). He further discusses practice-changing initiatives, like using sevoflurane instead of desflurane as an anesthetic to reduce environmental impact, and explains his work on improving the logistics of blood transfusions to lessen their ecological footprint.

Finally, Dr. Hibbs encourages hematologists to focus on actionable steps to minimize their environmental impact, advocating for practical changes in clinical practices and increased awareness of the healthcare sector's contribution to global emissions.

Host: Dr Sarah de Vlieger

Guest: Dr Stephen Hibbs

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us in this podcast episode, exploring with Prof Matteo Della Porta (Humanitas Research Hospital, Milano, Italy) the emerging role of "synthetic patients" in hematological clinical trials. Innovative generative artificial intelligence models allow today to create synthetic data set based on real patients, suitable to be used as control groups in clinical trials, helping in the identification of disease mechanisms and improving the prognostic risk prediction.

Prof Della Porta will dig into the challenges and opportunities linked to these new technologies, from the overcoming of privacy barriers to the regulatory needs required with the advent of synthetic data in clinical trial settings, opening the door for novel models in clinical research.

Host: Dr Enrica Orsini

Guest: Prof Matteo Della Porta

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an insightful interview with Prof Bruno Paiva from Clinical University of Navarra in Pamplona, Spain, as he and our host Dr. Isabel Olivera-Martinez, discuss the latest technical approaches to improving monitoring, risk stratification and differential diagnosis of patients with monoclonal gammopathies including MGUS (monoclonal gammopathy of unknown significance), smoldering myeloma and multiple myeloma.  

Prof Paiva begins by highlighting the importance of developing less invasive tools to assess MRD, given that multiple myeloma patients are living longer and need to be monitored multiple times. 

He further describes the potential updates to the guidelines of the International Myeloma Working Group that may include the use of mass spectrometry, as a more sensitive method to quantify the M-component as well as the application of next-generation techniques - such as next-generation flow cytometry and next-generation sequencing- to monitor disease in peripheral blood, as a complement to bone marrow assessments.

Prof Paiva also discusses the two largest ongoing translational studies, which aim to elucidate the “unknown” and define the clinical significance of MGUS and smoldering myeloma for each individual patient. 

Host: Isabel Olivera-Martinez, PhD, Medical Writer 

Guest: Prof Bruno Paiva

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an interview with Prof Ivo Touw, who has received the prestigious EHA David Grimwade Award for his contributions to the field of hematology research. Prof Touw and his research group focus on molecular signaling in leukemia predisposition syndromes, such as severe congenital neutropenia (SCN). They have described the dysfunction of the membrane receptor for the growth factor G-CSF and its role in SCN and malignant transformation to acute myeloid leukemia. In this interview prof.

Touw talks about his career path and choices that he has made along the way. He tells about his early fascination with the growth factors and how leukemia cells respond to them, which has driven his scientific career ever since. The simple questions such as “how can the growth factor in some cells only induce a proliferative response and in others both proliferation and differentiation?” or “why does one patient respond to G-SCF therapy and another does not?” triggered the discoveries of the complex underlying biological mechanisms.

If you want to hear about the stepwise discoveries of the roles of G-SCF mutants, RUNX gene and inflammatory stress and using novel technologies such as induced pluripotent stem (iPS) technology, CRISPR technology and computational biology, tune in to this episode with Prof Ivo Touw. He will also share his thoughts on the new avenues for thinking about therapy for SCN, such as repairing stem cells for autologous transplant or repurposing already available drugs.  

Host: Isabel Olivera-Martinez, PhD, Medical Writer

Guest: Prof Ivo Touw

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an insightful interview with Professor Saskia Middeldorp from Radboud University Medical Center in Nijmegen, The Netherlands, as she and our host Dr. Isabel Olivera-Martinez, discuss the medical and ethical challenges of conducting randomized clinical trials to prevent venous thromboembolism (VTE) during pregnancy. 

VTE is a leading cause of maternal morbidity and mortality, and poses significant risks to pregnant women. Together, explore the relevance of prophylactic treatments like low molecular weight heparin, and the ethical and financial complexities of conducting trials in this population. Learn about the ALIFE2 trial results, that assessed whether LMWH heparin should be used in women with recurrent miscarriage and inherited thrombophilia; well as the latest research and guidelines aimed at improving care for pregnant women at risk of VTE. 

Host: Isabel Olivera-Martinez, PhD, Medical Writer

Guest: Prof Saskia Middeldorp

If you liked this podcast and would like to explore related content, you can check out our clinical case about Thrombosis and Hemostasis on the EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an insightful interview with Professor Frank Leebeek from Erasmus University in Rotterdam, The Netherlands, as he discusses together with our host, Dr. Isabel Olivera-Martinez, the potential of gene therapy to free hemophilia patients from the standard coagulation factor replacement therapy.

Prof. Leebeek explains how gene therapy for hemophilia is carried out and differentiates the current possibilities for hemophilia A patients versus those with hemophilia B. He also highlights the advantages and challenges of this life-changing therapy, including its long-term effects, while addressing patient concerns related to safety and accessibility. Finally, he provides a glimpse into the future of gene therapy.

Host: Isabel Olivera-Martinez, PhD, Medical Writer

Guest: Prof Frank Leebeek

If you liked this podcast and would like to explore related content, you can check out our EHA Gene Therapy Techniques Program on the EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

In this podcast episode, we will explore the application of artificial intelligence to morphological diagnosis in hematology. Listening to our host, Dr Mahesh Prahladan (University of Suffolk, UK) you will learn how innovative machine learning and deep learning models have led to the development of AI systems that have been applied in various areas of hematology, including digital pathology.  

As these systems have shown promise in improving diagnostic accuracy and efficiency, they also have a potential for enlarging accessibility to precise diagnostics, through remote digital morphology, and have potential applications in the prognostic stratification of patients.

According to Dr Prahladan, we are not ready to dispose of our microscopes yet, but automation may become a useful and time-saving tool in the hands of morphologists.   

Host: Dr Enrica Orsini

Guest: Dr Mahesh Prahladan

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain), the first academic centre to achieve the authorisation to treat patients with a CAR T therapy developed 100% by academia. 

Prof Delgado discusses the complexities of obtaining regulatory approval for CAR T-cell therapy,  under the EU regulation for advanced therapy medicinal products (ATMPs).

In this episode, Prof Delgado shares his own experience learning to navigate the EU regulatory expectations while working at the European Medicines Agency (EMA). He emphasizes the importance of scientists understanding these regulations and regulators understanding the specific position of academia in the approval pathway for ATMPs. Listen and take advantage of his valuable insights! 

Host: Isabel Olivera-Martinez, Medical Writer

Guest: Prof Julio Delgado

This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for this podcast discussing the promises and challenges of academic and point-of-care CAR T-cell manufacturing with Dr Anna Sureda, president of EBMT (European Society for Blood and Marrow Transplantation). 

Dr Sureda provides her expert point of view on how CAR T-cells produced in academic centres may enhance patient access to CAR-T treatment, reducing costs and turnround times for production, and on the regulatory and quality issues linked to decentralized manufacturing of CAR T-cells. 

Discover the current European landscape for academic CAR-T production, the evidence and experiences accumulated so far, and the potential role of scientific societies such as EBMT and EHA in shaping the future of CAR-T treatment. 

Host: Enrica Orsini 

Guest: Dr Anna Sureda

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe 

Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain) as he explains the intricate process of CAR T-cell therapy. In this episode, we cover the key steps involved in CAR T, such as patient identification, apheresis, manufacturing, cell infusion and managing post-infusion related toxicities.

Prof Delgado offers expert insights on each component of this complex treatment and discusses possible improvements. He also highlights efforts to shorten vein-to-vein time and the importance of academic and non-profit manufacturing in reducing costs. This conversation offers a solid overview for clinicians and hematologists interested in advanced therapy medicinal products (ATMPs). 

Host: Isabel Olivera-Martinez, Medical Writer

Guest: Prof Julio Delgado

This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe